Chemotargets Announces First AI-Designed Drug for Huntington’s Disease to Enter Clinical Trials

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

This is a Biotech company founded in 2006 by Dr. Jordi Mestres as a spin-off from the Hospital del Mar Medical Research Institute (IMIM)

Read more

Dr. Scott Boyer joins Chemotargets as new CEO

by GENESIS Biomed

With the new incorporation, the company consolidates its transition from a software business to an AI-driven biotech

Read more

Chemotargets one of the top-20 Spanish biotech companies to watch according to the technology magazine of the Financial Times

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

This month Sifted, the technology magazine of the Financial Times, has contacted various experts in the technology industry and in analyzing data on investments, has concluded that the Spanish entrepr...

Read more

Alliance between the IMIM and Chemotargets to accelerate the design of new cancer therapies

by Parc Científic de Barcelona

The company Chemotargets –based in the Barcelona Science Park and a leader in in the global market as a provider of intelligence and drug design prediction platform– has signed a strategic agreeme...

Read more

The FDA licenses Chemotargets CLARITY platform

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

Chemotargets -a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park- has signed a license agreement for its CLARITY® pla...

Read more

Chemotargets opens an investment round of 15M euros to enter a new phase of growth

by GENESIS Biomed

Chemot​argets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to become a biotechnology company that will develop new medicines...

Read more

Chemotargets opens an investment round to enter a new phase of growth

by GENESIS Biomed

GENESIS Biomed and CREA Inversión will advise in the funding, which will allow the company to expand its activity in the discovery of new drugs

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

A chip against chronic bacterial infecti...

by IBEC - Institut de Bioenginyeria de Catalunya

IBEC researchers develop a device that allows to grow biofilms and ana...

Photos Stream